Skip to content
LATEST
Health

WILSERDLY gains first FDA-cleared companion test

Foundation Medicine says ESR1 mutations appear in up to 40% of eligible post-CDK inhibitor patients, making testing central to patient selection.

WILSERDLY gains first FDA-cleared companion test

Foundation Medicine said in a Roche investor-relations press release on Nov. 20 that the FDA approved FoundationOne®Liquid CDx as the first U.S. companion diagnostic for WILSERDLY plus everolimus.

The decision creates a regulated testing route for patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer; Foundation Medicine said ESR1 mutations occur in up to 40% of patients after CDK inhibitor treatment.

A companion diagnostic is a test used to identify patients who may be eligible for a specific therapy. In this case, Foundation Medicine said the blood-based test can help identify patients for WILSERDLY, also known as giredestrant, in combination with everolimus.

Foundation Medicine said the approval brings its total to nine FDA-approved companion diagnostic indications in breast cancer, which it described as the most held by any comprehensive genomic profiling company. It also said it has more than 100 approved companion diagnostic indications globally.

“FoundationOne Liquid CDx has the sensitivity necessary to detect ESR1,” Vera Grossmann said in the company announcement. Jean A. Sachs said, “We are excited to see a new therapy option and a high-quality companion diagnostic.”

The announcement places the approval in a common breast cancer subtype. Foundation Medicine said ER-positive, HER2-negative breast cancer accounts for about 70% of breast cancer cases.

FoundationOne Liquid CDx uses circulating cell-free DNA, which is genetic material shed into the blood. Foundation Medicine said the test analyzes 324 genes and is FDA-approved to report short variants in 311 genes, rearrangements in 8 genes and copy number alterations in 3 genes.

The company said FoundationOne Liquid CDx is covered by Medicare for patients with advanced cancer. The announcement did not provide commercial launch timing or adoption targets.

The approval is a regulatory decision about identifying patients for a therapy combination. It is not, by itself, a new clinical trial result, and the announcement did not provide new survival, response-rate or safety data for WILSERDLY plus everolimus.

Source: company press release, Roche Investor Relations, Nov. 20, 2026

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news